Bio-Techne (TECH) official guidance
Bio-Techne (TECH) official earnings guidance and management outlook. Each figure management stated is shown with its revisions and the source quote.
See the full Filings Intelligence suiteTECHBIO-TECHNE CorpQ4 FY2026 · ends 2026-06-30
4 metrics3 new1 maintainedearnings call · 2026-05-07 04:00:59 UTC
2026-05-07 04:00:59 UTC100 bpsnew100 bps vs Q4 FY2025
From a margin perspective, we remain focused on balancing growth investments with operational efficiency and intend to close the last quarter of the year with approximately 100 basis points of margin expansion over the prior year.
TECH · transcript · Q3 FY2026
2026-05-07 04:00:00 UTCOpen source
2026-05-07 04:00:59 UTC150 bpsmaintained150 bps vs Q4 FY2025
This customer-specific headwind moderates in the fourth quarter, impacting growth by approximately 150 basis points year-over-year and will be fully out of our comparisons as we enter fiscal 2027.
TECH · transcript · Q3 FY2026
2026-05-07 04:00:00 UTCOpen source
2026-02-05 05:01:33 UTC100 bps – 200 bpsnew100 bps – 200 bps vs Q4 FY2025
And then we're thinking of the impact to be 300 basis points and then somewhere around 150, anywhere between 100 and 200 for Q4, and then a total reset.
TECH · transcript · Q2 FY2026
2026-02-05 05:00:00 UTCOpen source
2026-05-07 04:00:59 UTCapproximately flatnew
Taking these market and customer-specific dynamics into account, we expect organic growth in the fourth quarter to be approximately flat.
TECH · transcript · Q3 FY2026
2026-05-07 04:00:00 UTCOpen source
2026-05-07 04:00:59 UTClow single-digit underlying growthnew1% – 3% vs Q4 FY2025
Excluding the impact of the cell therapy headwinds, we anticipate low single-digit underlying growth across the remainder of the portfolio.
TECH · transcript · Q3 FY2026
2026-05-07 04:00:00 UTCOpen source
TECHBIO-TECHNE CorpFY2027 · ends 2027-06-30
1 metric1 newearnings call · 2026-05-07 04:00:59 UTC
2026-05-07 04:00:59 UTCat least 4%new4% vs FY2026
Yeah, with regards to fiscal year 2027, I mean, based off the lens we have right now, yeah, we ought to be disappointed if we didn't do at least mid-single-digit growth because all the indicators are pointing towards a gradual normalization of the market.
TECH · transcript · Q3 FY2026
2026-05-07 04:00:00 UTCOpen source
TECHBIO-TECHNE CorpFY2026 · ends 2026-06-30
1 metricearnings call · 2026-02-05 05:01:33 UTC
2026-02-05 05:01:33 UTC100 bps100 bps vs FY2025
We're pleased with the upside delivered in Q1 and Q2, and remain on track to achieve 100 basis points of operating margin expansion for the full fiscal year.
TECH · transcript · Q2 FY2026
2026-02-05 05:00:00 UTCOpen source
2025-11-06 05:00:59 UTCat least 100 bpsnew100 bps vs FY2025
We're pleased with the margin upside delivered in Q1 and remain on track to achieve at least 100 basis points of margin expansion for the full fiscal year.
TECH · transcript · Q1 FY2026
2025-11-06 05:00:00 UTCOpen source
TECHBIO-TECHNE CorpQ3 FY2026 · ends 2026-03-31
3 metrics3 newearnings call · 2026-02-05 05:01:33 UTC
2026-02-05 05:01:33 UTC300 bpsnew300 bps vs Q3 FY2025
We expect this headwind to moderate slightly in Q3, impacting growth by approximately 300 basis points year-over-year, before moderating further in our fourth quarter and then being completely out of our year-over-year comparisons in fiscal 2027.
TECH · transcript · Q2 FY2026
2026-02-05 05:00:00 UTCOpen source
2026-02-05 05:01:33 UTC100 bpsnew100 bps vs Q3 FY2025
This timing benefit in Q2 will now be 100 basis points headwind to Q3.
TECH · transcript · Q2 FY2026
2026-02-05 05:00:00 UTCOpen source
2026-02-05 05:01:33 UTCconsistent with Q2new
Taking these customer-specific headwinds into account, we anticipate overall Q3 organic growth to be consistent with Q2.
TECH · transcript · Q2 FY2026
2026-02-05 05:00:00 UTCOpen source
TECHBIO-TECHNE CorpFY2026 · ends 2026-06-30
1 metric1 maintainedearnings call · 2026-02-05 05:01:33 UTC
2026-02-05 05:01:33 UTClow single-digitmaintained1% – 3% vs FY2025
Make sure, yeah. So, like, we haven't come off our low single-digit view for the full year, and that would require mid-single-digit growth in Q4, at least, yes.
TECH · transcript · Q2 FY2026
2026-02-05 05:00:00 UTCOpen source
2025-11-06 05:00:59 UTClow single digitsnew1% – 3% vs FY2025
With some positive signs from the other end markets that we serve, we feel that the low single digits for the year is still very, very feasible.
TECH · transcript · Q1 FY2026
2025-11-06 05:00:00 UTCOpen source
TECHBIO-TECHNE CorpQ4 FY2026 · ends 2026-06-30
1 metric1 newearnings call · 2026-02-05 05:01:33 UTC
2026-02-05 05:01:33 UTCmid-single-digit growthnew4% – 6% vs Q4 FY2025
Make sure, yeah. So, like, we haven't come off our low single-digit view for the full year, and that would require mid-single-digit growth in Q4, at least, yes.
TECH · transcript · Q2 FY2026
2026-02-05 05:00:00 UTCOpen source
TECHBIO-TECHNE CorpH4 FY2026 · ends 2026-06-30
1 metric1 newearnings call · 2025-11-06 05:00:59 UTC
2025-11-06 05:00:59 UTCpositive organic growthnew
As we lap prior year headwinds that began with the U.S. administration's policy changes in early calendar 2025, we expect a return to positive organic growth in the second half of the fiscal year.
TECH · transcript · Q1 FY2026
2025-11-06 05:00:00 UTCOpen source
TECHBIO-TECHNE CorpQ2 FY2026 · ends 2025-12-31
1 metric1 newearnings call · 2025-11-06 05:00:59 UTC
2025-11-06 05:00:59 UTCconsistent with Q1new
Despite these headwinds, we anticipate overall Q2 organic growth to be consistent with Q1.
TECH · transcript · Q1 FY2026
2025-11-06 05:00:00 UTCOpen source